Dr. McKean on the Importance of Molecular Profiling in Metastatic Melanoma

Source: OncLive, February 2022

Meredith McKean, MD, MPH
Supplements And Featured Publications, Emerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors, Volume 1, Issue 1

Meredith McKean, MD, MPH, associate director, Melanoma and Skin Cancer Research Program, Sarah Cannon Research Institute of Tennessee Oncology, discusses the importance of molecular profiling in melanoma.

The role of molecular testing has grown beyond only looking for BRAF V600E mutations, so clinicians should be ordering full comprehensive profiling for all patients with metastatic melanoma, McKean says. This is to ensure the identification of driver mutations, as well as to understand what clinical trials may be available for patients harboring mutations other than BRAF V600E, McKean explains.

Moreover, the field is generating excitement surrounding clinical trial opportunities to develop new avenues of treatment for patients with metastatic melanoma, McKean concludes.